Hoffmann-La Roche
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Inclusion Criteria * Signed cohort-specific Informed Consent Form * Age \>= 18 years at time of signing Informed Consent Form * Biomarker eligibility as determined by: * A validated test approved by local health authorities for detection of the specified biomarkers/mutations. * A validated test performed at a College of American Pathologists/clinical laboratory improvement amendments (CAP/CLIA) -certified or equivalently accredited diagnostic laboratory using a validated test for detection of the specified biomarkers. * Prior test results completed before signing cohort-specific Inform…
Inavolisib will be administered orally as per schedule specified in the respective arms.
Bevacizumab IV will be administered as per schedule specified in the respective arm.
Cetuximab IV will be administered as per schedule specified in the respective arm.
Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
SY-5609 will be administered by mouth as per schedule specified in the respective arm.
Divarasib will be administered orally as per schedule specified in the respective arms.
FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
FoundationOne®Liquid CDx is used to identify presence of genomic alterations for participant cohort assignment.